Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

ABSTRACT: BACKGROUND: Renal cell carcinoma is a disease marked by a unique biology which has governed it's long history of poor response to conventional cancer treatments. The discovery of the signaling pathway activated as a result of inappropriate constitutive activation of the hypoxia inducible factors (HIF), transcription factors physiologically and transiently stabilized in response to low oxygen, has provided a primary opportunity to devise treatment strategies to target this oncogenic pathway. OBJECTIVE: A review of the molecular pathogenesis of renal cell cancer as well as molecularly targeted therapies, both those currently available and those in development, will be provided. In addition, trials involving combination or sequential targeted therapy are discussed. METHODS: A detailed review

SUBMITTER: Cowey CL 

PROVIDER: S-EPMC2906134 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature